Lucilorla Lorlatinib 100mg Tablets 30's

The Lucilorla 100 mg Tablet contains Lorlatinib, a kinase inhibitor. It is an oral prescription medicine used to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

The Lucilorla 100 mg Tablet is taken once daily, with or without food, as prescribed by an oncologist.

• ALK-positive metastatic non-small cell lung cancer (NSCLC): It is used to treat adults whose NSCLC has spread to other parts of the body and has been confirmed to be ALK-positive.
• Before starting treatment, testing is performed to confirm that the tumor has an ALK alteration suitable for treatment with Lorlatinib.

The Lucilorla 100 mg Tablet contains Lorlatinib, which blocks the activity of ALK, a protein that can help certain cancer cells grow and survive when it is abnormally activated.

By inhibiting ALK signalling, Lorlatinib can slow or stop the growth and spread of ALK-positive cancer cells. It can also act against certain ALK alterations that may develop during treatment with other ALK-targeted medicines.

Take the Lucilorla 100mg Tablet exactly as prescribed by your doctor.

• The usual recommended dose is 100 mg once daily, with or without food. Take it at approximately the same time each day.
• Swallow the tablet whole with water. Do not chew, crush, or split the tablet. Do not take a tablet that is broken, cracked, or otherwise damaged.
• If you miss a dose, take it when you remember unless your next dose is due within 4 hours. Do not take two doses at the same time to make up for a missed dose.
• If you vomit after taking Lorbriqua, do not take an additional tablet. Take the next dose at the usual scheduled time.

Your doctor may reduce the dose to 75mg once daily and then to 50mg once daily if you develop certain side effects. Do not change the dose or stop treatment on your own.

Common:

Swelling or edema

Weight gain

Peripheral neuropathy

Changes in thinking or memory

Fatigue

Diarrhoea

Shortness of breath

Joint pain

High cholesterol

High triglycerides

Mood changes

Cough

Nausea

Constipation

Vomiting

Headache

Dizziness

High blood pressure

Vision changes

Muscle pain

Back pain

Reduced appetite

Fever

Rash

Some of these effects may be detected through blood tests, particularly increases in cholesterol, triglycerides, blood sugar, or liver enzymes.

Serious:

• Central nervous system effects: Seizures, severe changes in thinking, confusion, hallucinations, significant mood changes, or changes in speech may occur.
• Interstitial lung disease/pneumonitis: This can cause serious or life-threatening inflammation of the lungs.
• Heart rhythm problems: Lucilorla can cause atrioventricular (AV) block, which affects the electrical conduction of the heart.
• Severe liver toxicity: The risk is particularly important when Lorlatinib is taken with strong CYP3A inducers.
• Severe hyperlipidemia: Marked increases in cholesterol or triglycerides may require treatment or a change in the Lorbriqua dose.
• Severe hypertension: Blood pressure can become significantly elevated during treatment.
• Severe hyperglycemia: Lorbriqua can cause or worsen high blood sugar.
• Severe allergic reactions: Seek urgent medical attention if you develop swelling, breathing difficulty, or other signs of a serious allergic reaction.

Contact your doctor promptly if you develop new breathing problems, severe neurological or mood changes, fainting, chest symptoms, severe headache, or other unusual symptoms.

Lucilorla can interact with medicines that affect Cytochrome P450 3A (CYP3A), an enzyme that helps the body break down many medicines.

Strong CYP3A inducers: Medicines such as rifampicin can significantly reduce Lorlatinib levels and may cause serious liver toxicity. These medicines should not be taken with Lorbriqua.

Moderate CYP3A inducers: These may reduce Lorlatinib levels and should generally be avoided. If their use cannot be avoided, your doctor may adjust the Lorlatinib dose.

Strong CYP3A inhibitors: Medicines such as itraconazole can increase Lorlatinib levels. Their use should generally be avoided, or the Lorlatinib dose may need to be reduced.

Fluconazole: Concomitant use should generally be avoided. If it cannot be avoided, your doctor may reduce the Lorlatinib dose.

Other medicines affected by Lorlatinib: Lorlatinib can reduce the levels of certain CYP3A and P-glycoprotein (P-gp) substrates, which may reduce their effectiveness.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements you take before starting Lorbriqua.

• Store the Lucilorla 100 mg Tablet below 30°C.
• Keep it out of the sight and reach of children.
• Do not use the tablets after the expiry date printed on the pack.
• Do not use the medicine if the pack is damaged or shows signs of tampering.
• Store the tablets in their original pack as directed by your pharmacist.

• Take the Lucilorla 100 mg Tablet at the same time each day to maintain a consistent treatment schedule.
• Do not stop treatment or change the dose without your oncologist's advice.
• Your doctor may regularly monitor cholesterol and triglyceride levels, as increases are common with Lorlatinib.
• Blood pressure and blood sugar should also be monitored during treatment.
• Your doctor may perform an ECG to monitor your heart rhythm, particularly if you have cardiac risk factors.
• Report a new or worsening cough, breathlessness, or fever immediately because these may indicate lung inflammation.
• Tell your doctor about every medicine, supplement, or herbal product you take before starting or while receiving Lorbriqua.
• Avoid grapefruit or grapefruit juice unless your doctor specifically advises that it is safe, as grapefruit can affect the metabolism of Lorlatinib.
• If you develop cognitive, mood, speech, or sleep changes, inform your doctor rather than adjusting the dose yourself.